Board Certified
MD, Medical Oncology (ABIM)

Education: Fellowship – University of Texas M.D. Anderson Cancer Clinic Heavily involved in drug research and development.

Publications: Cyclooxygenase-2 Derived Prostaglandin E2 Protects Mouse Embryonic Stem Cells from Apoptosis(p 1096-1103) Jun-Yang Liou, David P. Ellent, Jennifer Goldsby,Bor-Sheng Ko, Nena Matijevic,Jaou-Chen Huang, Kenneth.K. Wu DOI: 10.1634/stemcells.2006-0505.

Gemtuzumab ozogamicin (Mylotarg) Prior to Allogeneic Hematopoietic Stem Cell Transplantation Increases the Risk of Hepatic Veno-occlusive Disease: American Society of Hematology (poster presentation) Blood. Stuart Goldberg, MD;David Ellent, MD; Dmitry Shtrambrand, MD; May Abdo-Matkiwsky, DO; Stephanie Hamarman, MD; Jack W Hsu, MD; Scott D Rowely, MD; and Andrew L Pecora, MD.

Autologous hematopoietic stem cell transplantation (HSCT) for the treatment of HIV-infected patients on HAART with non-Hodgkin’s lymphoma: D.P. Ellent, S.D. Rowely, S.L. Goldberg. A.L. Pecora, J.W. Hsu, D.S. Siegel; University of Medicine and Dentistry of New Jersey, Newark, NJ; Hackensack University Medical Center, Hackensack NJ Proc Am Soc Clin Oncol 22: page 600, 2003 (abstr 2414)

Research and Presentations:

City wide conferences within Houston Texas 2002 ASH Annual Meeting- poster presentation- Gemtuzumab ozogamicin (Mylotarg) Prior to Allogeneic Hematopoietic Stem Cell Transplantation increases the risk of Hepatic Veno-occlusive Disease,2003 ASCO Annual Meeting – poster presentation- Autologus hematopoietic stem cell transplantation (HSCT) for the treatment of HIV- infected patients on HAART with non-Hodgkin’s Lymphonam in HIV positive patients and extensive investigation of venoclusive disease after administration of Mylotarg Research investigation pathways of differentiation of stem cells.

22751 Professional Dr. Ste 140 Kingwood, TX 77339
Click here for direction https://goo.gl/maps/vrPVAmKSTbWdWrKv9

Share this information:

David P Ellent

David P Ellent MD

Oncology, CEO and Founder

Phone:

281-975-1000

Fax: 281.312.1338